Key result
Apparently resistant hypertension is linked to higher metabolic syndrome prevalence, at.
Why the study?
Hypertension is a significant cardiovascular disease risk factor, and a subset of patients has apparently resistant hypertension with inadequately controlled blood pressure despite treatment.
Cross-Sectional (n=52,012)
Yes
Middle-aged men with apparently resistant hypertension have a significantly higher burden of cardiovascular risk factors and lower treatment success rates compared to those with non-resistant treated hypertension, highlighting the need for aggressive multifactorial risk management.
Answers are grounded in this paper and cite their sources.
Apparent resistant hypertension signals higher cardiometabolic burden in middle-aged men; supports targeted screening but leaves open whether modification improves outcomes.
Background/Objectives: Hypertension (HTN) is a significant risk factor for cardiovascular disease (CVD), and a subset of patients exhibits apparently resistant hypertension (aRHTN), where blood pressure remains inadequately controlled despite treatment. This study aims to assess the prevalence of cardiovascular risk factors in middle-aged Lithuanian men with HTN and aRHTN, as well as to evaluate the effectiveness of hypertension management in these groups. Methods: Data from 52,012 men participating in the Lithuanian High Cardiovascular Risk Programme (LitHiR) between 2009 and 2019 were analysed. Participants were categorised into two groups: treated hypertension (HTN) and apparent resistant hypertension (aRHTN). Despite treatment, the aRHTN group included those who failed to achieve their target blood pressure. The prevalence of cardiovascular risk factors (dyslipidaemia, diabetes, metabolic syndrome, obesity, physical inactivity, and an unbalanced diet) was compared between the groups. Results: The overall prevalence of HTN was 47%, with 9.9% of treated hypertensive men having aRHTN. Dyslipidemia was both groups’ most prevalent risk factor (94.1% in HTN vs. 95.5% in aRHTN, p < 0.001). Men with aRHTN exhibited higher rates of diabetes (25.9% vs. 18.5%, p < 0.001), metabolic syndrome (75.3% vs. 66.3%, p < 0.001), and left ventricular hypertrophy (59.4% vs. 43.1%, p < 0.001). Treatment success was significantly lower in the aRHTN group (7.57% vs. 28.4%, p < 0.001). Conclusions: Hypertension affects almost half of the studied population, with 10% of treated hypertensives exhibiting aRHTN. The aRHTN group had a higher number of additional cardiovascular risk factors and lower treatment success rates. Improved management of cardiovascular risk factors is crucial, especially in the aRHTN population, to reduce the burden of CVD.
No takes yet. Share an insight, caveat, or question.
Šileikienė et al. (2025) conducted a cross-sectional in Hypertension and Apparently Resistant Hypertension (n=52,012). Apparently resistant hypertension (aRHTN) vs. Treated hypertension (HTN) was evaluated on Prevalence of metabolic syndrome (p=<0.001). Apparently resistant hypertension in middle-aged men was associated with higher rates of metabolic syndrome, diabetes, and left ventricular hypertrophy compared to treated hypertension.
Synapse has enriched 10 related papers. Consider them for comparative context: